2022 Seattle, WA, Patient and Family Virtual Conference
Please find the presentation materials below.
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Please find the presentation materials below.
Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant.
Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials.
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
View each session from the San Antonio Patient and Family Virtual Conference with the links below:
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with
In this conference session, Dr. Amer Zeidan, MD discusses understanding the management options for higher risk MDS, the evolution of MDS to AML and more.
In this conference session, Dr. Krisstina Gowin DO discusses best practices when living with